- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Galecto-Aktie erreicht 52-Wochen-Tief bei 6,46 US-Dollar | 1 | Investing.com Deutsch | ||
| Fr | Galecto stock hits 52-week low at $6.46 amid market challenges | 4 | Investing.com | ||
| 01.11. | Galecto reports Q3 results | 1 | Seeking Alpha | ||
| GALECTO Aktie jetzt für 0€ handeln | |||||
| 01.11. | Galecto, Inc.: Galecto Reports Third Quarter 2024 Financial Results | 74 | GlobeNewswire (Europe) | - Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets... ► Artikel lesen | |
| 01.11. | Galecto, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.10. | Galecto (NASDAQ:GLTO) Price Target Increased to $10.00 by Analysts at Oppenheimer | 3 | MarketBeat | ||
| 17.10. | Oppenheimer raises Galecto stock target, outperform on strategic focus | 2 | Investing.com | ||
| 15.10. | Galecto, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.10. | Galecto, Inc.: Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler | 3 | GlobeNewswire (USA) | ||
| 07.10. | Why Galecto (GLTO) Shares Are Down 27% Today | 3 | Benzinga.com | ||
| 07.10. | Galecto buys leukemia drug from Bridge Medicines, drops bone cancer asset in strategic pivot | 1 | FierceBiotech | ||
| 07.10. | Galecto To Focus On Clinical Stage Compound GB1211; Obtains Global Rights To BRM-1420 | - | RTTNews | ||
| 07.10. | Galecto, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.10. | Galecto fokussiert sich auf Krebs und erwirbt Rechte an neuartigem AML-Medikament | 11 | Investing.com Deutsch | ||
| 07.10. | Galecto, Inc.: Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines | 6 | GlobeNewswire (USA) | ||
| 18.09. | Galecto, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 11.09. | Galecto announces reverse stock split, shares adjusted | 5 | Investing.com | ||
| 05.09. | Galecto, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.08. | Galecto announces 1-for-25 reverse stock split | 2 | Seeking Alpha | ||
| 28.08. | Galecto, Inc.: Galecto Announces Reverse Stock Split | 113 | GlobeNewswire (Europe) | BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced... ► Artikel lesen |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 10,070 | +1,67 % | BASF, Evotec, GFT, Knaus Tabbert, LVMH, Wienerberger - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | -100,00 % | New Core One 3D Printer From Prusa May Be the Answer to Its Bambu Problem | ||
| PALATIN TECHNOLOGIES | 0,865 | +0,70 % | Palatin Technologies Inc. Loss At -$7.82 Mln In Q1 | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) announced Loss for first quarter of -$7.82 millionThe company's earnings totaled -$7.82 million, or -$0.39 per share. This compares with... ► Artikel lesen | |
| MAINZ BIOMED | 0,198 | -5,84 % | Mainz Biomed und Thermo Fisher Scientific unterzeichnen Kooperationsvereinbarung | ||
| VIKING THERAPEUTICS | 50,48 | +3,19 % | Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs | ||
| TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| CENTOGENE | 0,070 | -1,41 % | Centogene NV: CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| AFFIMED | 2,640 | +0,76 % | Affimed N.V.: Affimed Reports Third Quarter 2024 Financial Results & Business Update | AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a... ► Artikel lesen | |
| GALAPAGOS NV | 24,000 | -0,17 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
| GINKGO BIOWORKS | 6,000 | -0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| CELLECTAR BIOSCIENCES | 1,420 | -4,05 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update | Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition Raised approximately $19.4 million with potential to raise... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,470 | +1,29 % | Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - ... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,725 | -5,22 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen |
Das Unternehmen GALECTO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 5,820 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GALECTO INC finden Sie auf Wallstreet Online.
